AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

AngioDynamics (ANGO) PT Lowered to $34 at Canaccord Genuity

January 7, 2022 7:21 AM EST

Canaccord Genuity analyst William Plovanic lowered the price target on AngioDynamics (NASDAQ: ANGO) to $34.00 (from $37.00) while maintaining a Buy rating following results and sector multiple compression.

The analyst commented, "ANGO reported FQ2/22 revenue of $78.3M (+7.6% Y/Y), beating our $77.7M estimate and consensus projection of $77.9M despite building a significant backlog due to manufacturing and shipping delays. ANGOs bottom line missed our... More